Marshall Wace North America’s Regenxbio RGNX Stock Holding History

Marshall Wace North America’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$301K	Buy	+7,200	New	+$259K	﹤0.01%	1242
2020 Q4	–	Sell	-171,862	Closed	-$4.73M	–	1537
2020 Q3	$4.73M	Sell	171,862 -175,199	-50%	-$5.71M	0.03%	407
2020 Q2	$12.8M	Buy	347,061 +87,514	+34%	+$3.26M	0.08%	236
2020 Q1	$8.4M	Buy	+259,547	New	+$10.8M	0.06%	243
2018 Q2	–	Sell	-223,901	Closed	-$6.68M	–	1634
2018 Q1	$6.68M	Buy	223,901 +183,650	+456%	+$5.34M	0.03%	494
2017 Q4	$1.34M	Buy	+40,251	New	+$1.21M	0.01%	927
2017 Q3	–	Sell	-24,526	Closed	-$491K	–	1461
2017 Q2	$491K	Buy	+24,526	New	+$475K	﹤0.01%	1096

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Marshall Wace North America's RGNX Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Regenxbio (RGNX) in Q3 2021: 7,200 shares worth $301K. The stake represents ﹤0.01% of the portfolio and ranks #1242 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in RGNX as recently as Q3 2020.

Marshall Wace North America first reported a position in RGNX in Q2 2017 and has held it in 7 quarters since. The position peaked at $12.8M in Q2 2020. 182 funds tracked by Wall St. Rank hold RGNX as of Q3 2021.

Marshall Wace North America held 7,200 shares of Regenxbio worth $301K as of Q3 2021.
Regenxbio was a new Marshall Wace North America position in Q3 2021.
Regenxbio made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1242 holding.
Marshall Wace North America first reported a position in Regenxbio in Q2 2017 and has held it in 7 quarters since.
Marshall Wace North America's Regenxbio position peaked at $12.8M in Q2 2020.
182 funds tracked by Wall St. Rank held Regenxbio as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.